TMC278 Long Acting Formulation

rilpivirine long-acting formulation · Janssen Research & Development, LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TMC278 Long Acting Formulation, covering 2016-04-07 to 2016-04-07. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate Safety, Acceptability, Pharmacokinetics, and ex Vivo Pharmacodynamics of TMC278 Long Acting Formulation in HIV-1 Seronegative Participants [Phase 1]

See pricing